THE CRAVE OF FIXED DOSE COMBINATION IN INDIAN MARKET

  • J. Balasubramanian
  • N. Radhika
  • A. V. Badarinath

Abstract

The aim of the present retrospective works reveals the need of fixed-dose combination (FDC) in Indian market as per the Indian regulations.
A combination drug most commonly refers to an FDC, which is a formulation including two or more active pharmaceutical ingredients combined in
a single dosage form, which is manufactured and distributed in certain respective fixed doses. This review outlines the FDCs rationale, guidelines on
data required for approval for marketing FDCs, marketing potential throughout the world. The safety of the combination drugs has to be thoroughly
evaluated, and there are considerations for the drugs that are already in the market as individual or single-drug entity. However, the safety profile of
the established drugs will alter when they are combined together. However, many of the irrational combinations are popular and widely prescribed
by physicians in our country. This study provides a comprehensive analysis of the current markets for FDC products throughout the world and the
market potential of promising drugs under development.

Keywords: Fixed dose combinations, Active pharmaceutical ingredients, Human immunodeficiency virus, Chronic obstructive pulmonary disease,
World Health Organization, Non-steroidal anti-inflammatory.

References

1. Lori Tucker, Donald Saxman, Anna Welch Crull. The Global Market For
Fixed –Dose Combination Drugs for Leading Diseases. Available from:
http://www.stix-market-research.com/stix publications/combinational
drugs.html. [Last accessed 2013 Dec ???].
2. Christopher Comfort. The COPD Drug Market Will Become More
Fractured As Several New Agents Reach The Market And Erode The
Dominance Of The Current Market Leaders.Available from: http://
www.decisionresources.com/News-and-Events/Press-Releases/COPD-
100912. [Last accessed 2012 Oct 9].
3. Julie McKenna. COPD Tops Asthma as the Focus Indication for
Next Generation Respiratory Therapies at the 2012 American
Thoracic Society Conference. Available from: http://www.photos.
prnewswire.com/prnh/20120531/NE16127-INFO. [Last accessed
2012 May 21].
4. BoehringerIngelheim to present highly anticipated Phase III data in IPF
and COPD at ATS International Conference, last accessed April 30,
2014.
5. Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters
such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion.
Available from: http://www.asdreports.com/ASDR-9495. [Last
accessed 2012 Mar ???].
6. Katherine L. Combination therapy in hypertension management. US
Pharm 2012;37(6):46-50.
7. FIXED-DOSE COMBINATIONS - Fixed-Dose Combination Products
– A Review. Available from: http://www.drug-dev.com/Main/Back-
Issues/FIXEDDOSE-COMBINATIONS-FixedDose-Combination-
Produ-673. [Last accessed 2014 Apr ???].
9. Collier R. Reducing the “pill burden”. CMAJ 2012;184(2):E117-8.
10. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for
recommending fixed-dose combination tablets for treatment of
tuberculosis. Bull World Health Organ 2001;79(1):61-8.
11. Ellard GA, Fourie PB. Rifampicin bioavailability: A review of its
pharmacology and the chemotherapeutic necessity for ensuring optimal
absorption. Int J Tuberc Lung Dis 1999;3 11 Suppl 3:S301-8.
12. Narendranath KG. Ban or curb on major fixed dose combinations
imminent, many anti-epileptic and mucolytic – antibiotics preparations
under critical review, 2000.
13. Sweetman SC. Martindale: The Complete Drug Reference. 33rd ed.
London: Pharmaceutical Press; 2002. p. 205-6, 215-7, 240-1.
14. Kaplan W. Fixed dose Combinations as an Innovative Delivery
Mechanism. Background papers to this are Available from: archives.
who.int/priority meds/report background/delivery.doc. [Last accessed
2004 Oct 7].
15. PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market
Analysis to 2022. Available from: http://www.reportlinker.com/
P02029804/. [Last accessed 2013 Jul 31].
17. Kulkarni SK. On the safety of nimesulide, a preferential COX-2
inhibitor. Curr Sci 2000;83(12):1442-3.
18. Chakraborti A. Fixed dose combinations in therapy. Express Pharm
2007;2(19):62-3.
19. Gautam CS, Saha L. Fixed dose drug combinations (FDCs): Rational or
irrational: A view point. Br J Clin Pharmacol 2008;65(5):795-6.
20. John LJ, Devi P, John J, Guido S. Drug utilization study of antimicrobial
agents in medical intensive care unit of a tertiary care hospital. Asian J
Pharm Clin Res 2011;4(2):81-4.
21. Sengar MR, Gandhi SV, Patil UP, Rajmane VS. Simultaneous
determination of diclofenac sodium and thiocolchicoside in fixed
dose combination by spectrophotometry. Asian J Pharm Clin Res
2010;3(2):89-91.
Statistics
232 Views | 2099 Downloads
How to Cite
Balasubramanian, J., N. Radhika, and A. V. Badarinath. “THE CRAVE OF FIXED DOSE COMBINATION IN INDIAN MARKET”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 7, no. 4, Sept. 2014, pp. 106-10, https://innovareacademics.in/journals/index.php/ajpcr/article/view/1498.
Section
Original Article(s)